A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

NCT04184622 · Completed

Last updated 2026-05-28

This study is testing the medication tirzepatide in adults who have obesity or are overweight to see how it affects body weight over time.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 2,539 people

Who can join Ages 18+ · all sexes

Timeline Started 2019-12 · est. completion 2024-07

Where 118 sites · Argentina, Brazil, China, India, Japan, Mexico, Puerto Rico, Russia, Taiwan, United States

What this study is testing ClinicalTrials.gov NCT04184622 ↗

Description as written by the study sponsor.

This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Percent Change From Baseline in Body Weight (Primary Treatment Period)
Sponsor	Eli Lilly and Company
Conditions studied	Overweight, Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04184622 ↗